Women are four times more likely than men to get diagnosed with multiple sclerosis (MS), an incurable disease that affects the central nervous system. Now, rates of MS are on the rise among Black women.
The U.S. Food and Drug Administration recently approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).
